4//SEC Filing
Boudes Pol F 4
Accession 0001415889-23-013903
CIK 0001006281other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 5:00 PM ET
Size
6.2 KB
Accession
0001415889-23-013903
Insider Transaction Report
Form 4
Boudes Pol F
Director
Transactions
- Award
Stock Options (Right to Buy)
2023-09-29+61,676→ 61,676 totalExercise: $1.66Exp: 2033-09-29→ Common Stock (61,676 underlying)
Footnotes (2)
- [F1]The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
- [F2]Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001454771
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 5:00 PM ET
- Size
- 6.2 KB